Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
38%(3 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_2
6
60%
Ph phase_1
4
40%

Phase Distribution

4

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
6(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (40.0%)
Phase 26 (60.0%)

Trials by Status

completed880%
terminated220%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

NCT01633541
terminatedphase_2

A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

NCT01285635
completedphase_2

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT00666666
terminatedphase_1

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00561197
completedphase_1

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

NCT00286793
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01633541Phase 2

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

Completed
NCT01285635Phase 2

A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

Terminated
NCT00666666Phase 2

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Completed
NCT00561197Phase 1

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Terminated
NCT00286793Phase 1

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Completed
NCT00275431Phase 2

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Completed
NCT00440388Phase 2

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Completed
NCT00286806Phase 1

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Completed
NCT00397293Phase 1

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Completed
NCT00286780Phase 2

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10